ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.0
  1. ホーム
  2. /化合物

Paroxetine Hydrochloride

HCID 62878
ノートを作成反応を作成見積依頼を出す
印刷プレビュー
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
130855-16-2
標準SMILES
Cl.Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1
InChIKey
GELRVIPPMNMYGS-RVXRQPKJSA-N
分子式
C19H21ClFNO3
平均分子量
365.8 g/mol
単同位体質量
365.11939943

概要

Paroxetine hydrochloride is the hydrochloride salt of paroxetine. It is an antidepressant drug. It has a role as an antidepressant, an anxiolytic drug, a P450 inhibitor, a hepatotoxic agent and a serotonin uptake inhibitor. It contains a paroxetinium(1+).

名称と識別子

優先名称
Paroxetine Hydrochloride
IUPAC
(3S,4R)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine;hydrochloride
英語名
(3S,4R)-3-((Benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine HCl
分子式
C19H21ClFNO3
分子量
365.8263432

名称と別名

Paroxetine hydrochloride78246-49-8Paroxetine HclParoxatPaxil CR3I3T11UD2SParoxetine hydrochloride [USP]Paroxetine Hydrochloride AnhydrousNSC-758654BRL29060ACHEBI:7944Paroxetine hydrochloride (USP)
名称をさらに表示
D6-Paroxetine HCl (Mixture of Enantiomers)(3S,4R)-3-((Benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine HCl
DTXSID50228914DeroxatPiperidine, 3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-, hydrochloride, (3S,4R)-Piperidine, 3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-, hydrochloride, (3S-trans)-Paxilcr CRRefChem:858692DTXCID00151405(-)-(3S,4R)-4-(p-Fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidine Hydrochloride

データベース識別子

CAS
130855-16-2、78246-49-8
PubChem CID
62878
DTXSID
DTXSID50228914
ChEMBL
CHEMBL1708、CHEMBL6067650
ChEBI
CHEBI:7944
UNII

物性

構造計算による物性

極性表面積
39.7 Ų
水素結合供与体数
2
水素結合受容体数
5
回転可能結合数
4
重原子数
25
形式電荷
0
複雑度
402

実験および物理化学的性質

Human Drugs · 2 件

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Collision Cross Section181.1 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

物理化学的性質

融点
116.4 · 116.4-118.4 °C

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Danger

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P261, P264, P264+P265, P270, P271, P273, P280, P301+P317, P304+P340, P305+P354+P338, P317, P319, P330, P391, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 58 reports by companies from 7 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Regulatory InformationParoxetine hydrochloride: Does not have an individual approval but may be used under an appropriate group standard
Hazard Classes and CategoriesAcute Tox. 4 (100%)

毒性情報

Treatment · 1 件

Treatment should consist of those general measures employed in the management of overdosage with any drugs effective in the treatment of major depressive disorder. Ensure an adequate airway, oxygenation, and ventilation. Monitor cardiac rhythm and vital signs. General supportive and symptomatic measures are also recommended. Induction of emesis is not recommended. Gastric lavage with a large-bore orogastric tube with appropriate airway protection, if needed, may be indicated if performed soon after ingestion, or in symptomatic patients. Activated charcoal should be administered. Due to the large volume of distribution of this drug, forced diuresis, dialysis, hemoperfusion, and exchange transfusion are unlikely to be of benefit. No specific antidotes for paroxetine are known. (L1712)

Exposure Routes · 1 件

Paroxetine hydrochloride is slowly, but completely absorbed following oral administration. Paroxetine mesylate salt is also completely absorbed after oral dosing. The oral bioavailability appears to be low due to extensive first-pass metabolism. Paroxetine hydrochloride oral tablets and suspension are reportedly bioequivalent. Absorption of either salt form is not substantially affected by food. Peak concentrations of Brisbelle (mesylate salt) were reached at 6 hours (3 to 8 hours range). Steady state Cmax was 13.10 ng/mL. The steady state AUC (0-last) was 237 hr*ng/mL. Paroxetine mesylate generally follows non-linear pharmacokinetics because CYP2D6, the enzyme that is part responisible for paroxetine metabolism, is readily saturable.

化学と産業

薬理情報

Metabolism/Metabolites · 1 件

Paroxetine is extensively metabolized after oral administration, likely in the liver. The main metabolites are polar and conjugated products of oxidation and methylation, which are readily eliminated by the body. The predominant metabolites are glucuronic acid and sulfate conjugates. Paroxetine metabolites do not possess significant pharmacologic activity (less than 2% that of parent compound). Paroxetine is metabolized by cytochrome P450 (CYP) 2D6. Enzyme saturation appears to account for the nonlinear pharmacokinetics observed with increasing dose and duration of therapy. Route of Elimination: Approximately 64% of a 30 mg oral solution of paroxetine was excreted in the urine with 2% as the parent compound and 62% as metabolites. Approximately 36% of the dose was excreted in the feces (via bile), mostly as metabolites and less than 1% as parent compound. Half Life: 21-24 hours

FDA Pharmacological Classification · 2 件

PAROXETINE HYDROCHLORIDE

Serotonin Uptake Inhibitors [MoA]; Serotonin Reuptake Inhibitor [EPC]

MeSH Pharmacological Classification · 3 件

A structurally and mechanistically diverse group of drugs that are not tricyclics or monoamine oxidase inhibitors. The most clinically important appear to act selectively on serotonergic systems, especially by inhibiting serotonin reuptake.

Compounds that specifically inhibit the reuptake of serotonin in the brain.

Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP2D6.

用途と製造

Uses · 1 件

Labeled indications include: major depressive disorder (MDD), panic disorder with or without agoraphobia, obsessive-compulsive disorder (OCD), social anxiety disorder (social phobia), generalized anxiety disorder (GAD), post-traumatic stress disorder (PTSD), and premenstrual dysphoric disorder (PMDD). Unlabeled indications include: eating disorders, impulse control disorders, vasomotor symptoms of menopause, obsessive-compulsive disorder (OCD) in children, and mild dementia-associated agitation in nonpsychotic individuals. Brisdelle, which consists of paroxetine mesylate is indicated for the treatment of moderate to severe vasomotor symptoms (like hot flashes) associated with menopause.

関連反応

12 件
反応記録を作成
HRID 247817 の反応式
HRID 247817反応物としてuspto-grants-1993_05
HRID 467064 の反応式
HRID 467064反応物としてuspto-grants-1992_10
HRID 483785 の反応式
HRID 483785反応物としてuspto-grants-1993_07
HRID 703845 の反応式
HRID 703845反応物としてuspto-grants-1991_01
HRID 989067 の反応式
HRID 989067生成物としてuspto-grants-2003_10
HRID 1379654 の反応式
HRID 1379654生成物としてuspto-grants-1997_09
HRID 1633551 の反応式
HRID 1633551生成物としてuspto-grants-2003_01
HRID 1633552 の反応式
HRID 1633552生成物としてuspto-grants-2003_01
1 / 2 ページ

化合物ノート

読み込み中…

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
その他の操作
ノートを作成反応を作成見積依頼を出す
3I3T11UD2S、5V22ESA4MA
EC Number
616-601-1
Toxicity Summary · 1 件

Paroxetine is a potent and highly selective inhibitor of neuronal serotonin reuptake. Paroxetine likely inhibits the reuptake of serotonin at the neuronal membrane, enhances serotonergic neurotransmission by reducing turnover of the neurotransmitter, therefore it prolongs its activity at synaptic receptor sites and potentiates 5-HT in the CNS; paroxetine is more potent than both sertraline and fluoxetine in its ability to inhibit 5-HT reuptake. Compared to the tricyclic antidepressants, SSRIs have dramatically decreased binding to histamine, acetylcholine, and norepinephrine receptors. The mechanism of action for the treatment of vasomotor symptoms is unknown.

Signs and SymptomsComa, dizziness, drowsiness, facial flushing, nausea, sweating, tremor, vomiting
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 6 件

Drug Induced Liver Injury Rank (DILIrank 2.0)

Paroxetine hydrochloride

vLess-DILI-concern

8

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

Toxicity DataLD50: 500mg/kg (Oral, Mouse) (A308)